

**CARCINOMA OF THE VAGINA**

1. **Specimen(s):** *list all specimens removed during case*
2. **Procedure(s):** *select all that apply*
  - a. [Incisional biopsy]
  - b. [Excisional biopsy]
  - c. [Wide-local excisional biopsy]
  - d. [Radical vaginectomy]
  - e. [Partial vaginectomy]
  - f. [Vaginectomy] (can further specify, e.g. "anterior vaginectomy")
3. **Sentinel Lymph Node Sampling:** *select whether or not sentinel lymph nodes were removed*
  - a. [Performed]
  - b. [Not performed]
  - c. [Not applicable]
  - d. [Cannot be determined]
4. **Regional Lymph Node Sampling:** *select whether or not regional, non-sentinel lymph nodes were removed*
  - a. [Performed]
  - b. [Not performed]
  - c. [Cannot be determined]
5. **Specimen Integrity:** *document whether intact or received fragmented. This absolutely requires correlating with the operative report*
6. **Primary Tumor Site:** *select all that apply*
  - a. [Upper third]
  - b. [Middle third]
  - c. [Lower third]
  - d. [Cannot be determined]
7. **Tumor Size:** *provide greatest dimension and total dimensions*
  - a. [Greatest dimension: <SPECIFY>]
  - b. [Total dimensions: <SPECIFY>]
  - c. [Cannot be determined]
8. **Tumor Focality:** *specify tumor focality*
  - a. [Unifocal]
  - b. [Multifocal]
  - c. [Cannot be determined]
9. **Histologic Type:** *select appropriate tumor type*
  - a. [Squamous cell carcinoma, keratinizing type]
  - b. [Squamous cell carcinoma, non-keratinizing type]
  - c. [Squamous cell carcinoma, basaloid type]

- d. [Squamous cell carcinoma, papillary type]
  - e. [Verrucous carcinoma]
  - f. [Paget disease, <SPECIFY INVASIVE OR NON-INVASIVE>]
  - g. [Adenocarcinoma, intestinal type]
  - h. [Mesonephric carcinoma]
  - i. [Clear cell carcinoma]
  - j. [Mucinous carcinoma]
  - k. [Endometrioid carcinoma]
  - l. [Adenosquamous carcinoma]
  - m. [Undifferentiated carcinoma]
  - n. [Carcinoma, not-otherwise-specified]
  - o. [Other, <SPECIFY>]
10. **Histologic Grade:** *specify histologic grade of tumor*
- a. [Well-differentiated (grade 1)]
  - b. [Moderately-differentiated (grade 2)]
  - c. [Poorly-differentiated (grade 3)]
  - d. [Undifferentiated (grade 4)]
  - e. [Other, <SPECIFY>]
    - i. If primary vaginal endometrioid carcinoma, use FIGO grading system
  - f. [Not applicable]
11. **Stromal Invasion:** *specify presence of stromal invasion*
- a. [Absent]
  - b. [Present, <PROVIDE DEPTH OF INVASION>]
12. **Lymph-Vascular Space Invasion:** *state whether LVI is present*
- a. [Absent]
  - b. [Present]
  - c. [Suspicious]
  - d. [Cannot be determined]
13. **Perineural Invasion:** *state whether PNI is present*
- a. [Absent]
  - b. [Present]
  - c. [Suspicious]
  - d. [Cannot be determined]
14. **Other Sites/Organs Involved:** *state whether there is disease outside the vagina*
- a. [Negative]
  - b. [Positive: <LIST OTHER ORGANS INVOLVED> ; <PROVIDE SIZE OF LARGEST METASTATIC FOCUS>]
15. **Additional Pathologic Findings:** *if possible, select all that apply*

- a. [None identified]
- b. [Low-grade squamous intraepithelial lesion (LSIL)]
- c. [High-grade squamous intraepithelial lesion (HSIL)]
- d. [Adenosis]
- e. [Adenocarcinoma in-situ]
- f. [Other, <SPECIFY>]

**16. Regional Lymph Node Status:** *provide total sentinel and non-sentinel lymph node status*

a. *It is important to indicate which lymph nodes are positive and how big the metastasis is because this affects staging.*

b. Sentinel Lymph Nodes:

- i. [Not performed]
- ii. If all lymph nodes are negative: [Negative: 0 / <PROVIDE TOTAL # OF SENTINEL LYMPH NODES>]
- iii. If there are lymph nodes with carcinoma:
  - 1. [Number of lymph nodes with metastasis greater than 0.02 cm (i.e. bigger than ITCs)]
  - 2. [Number of lymph nodes with isolated tumor cells (ITCs; single cells or small clusters of cells not more than 0.02 cm in greatest dimension)]
  - 3. [State presence/absence of extranodal extension]
  - 4. [Give total number of sentinel lymph nodes]

c. Total Lymph Nodes:

- i. [Not performed]
- ii. If all lymph nodes are negative: [Negative: 0 / <PROVIDE TOTAL LYMPH NODES>]
- iii. If there are lymph nodes with carcinoma:
  - 1. [Total number of lymph nodes with metastasis greater than 0.02 cm (i.e. bigger than ITCs)]
  - 2. [Total number of lymph nodes with isolated tumor cells (ITCs; single cells or small clusters of cells not more than 0.02 cm in greatest dimension)]
  - 3. [Indicate the anatomic site of the positive lymph node(s)]
  - 4. [State presence/absence of extranodal extension]
  - 5. [Give grand total # of lymph nodes (i.e. sentinel + non-sentinel)]

**17. Cytology:** *state whether or not cytology was performed and results, include accession number*

- a. [Not performed]
- b. [Performed]:
  - i. [Positive, <PROVIDE ACCESSION NUMBER IF AVAILABLE>]
  - ii. [Negative, <PROVIDE ACCESSION NUMBER IF AVAILABLE>]

**18. Surgical Margins:** *select appropriate margin status*

- a. [Negative for carcinoma] (use if there is no significant background SIL or D-VAIN)
- b. [Negative for invasive and in-situ carcinoma] (use if there is significant background SIL or D-VAIN)
- c. [Positive for invasive carcinoma; <STATE SPECIFIC MARGIN>, <STATE FOCAL OR DIFFUSE>, <PROVIDE APPROXIMATE LINEAR EXTENT>]
- d. [Positive for in-situ carcinoma only; <STATE SPECIFIC MARGIN>, <STATE FOCAL OR DIFFUSE>, <PROVIDE APPROXIMATE LINEAR EXTENT>]
- e. [Cannot be determined]

**19. Pathologic Staging:** *may use AJCC and/or FIGO; refer to staging manuals*

\*Primary endometrioid tumors of the vagina must be distinguished from recurrent/metastatic endometrioid adenocarcinoma of uterine primary.

\* Non-epithelial vaginal malignancies include mesenchymal (sarcoma botryoides, leiomyosarcoma, endometrial stromal sarcoma, aggressive angiomyxoma, etc), melanocytic, and germ cell tumors. Grading and staging of these tumors is not included in the TNM system for the vagina and instead may use different grading and staging schema.